SecBot SecBot
SC 13G/A ·Filed Sep 22, 2026

HBIO

HARVARD BIOSCIENCE INC
NEUTRAL
Impact 3/10
Horizonweeks Processed1mo ago SEC0001019432-26-000013
Passive stake amendment
Actionable Insight • Neutral

Monitor for any future conversion to Schedule 13D if Leviticus Partners increases engagement or seeks board representation. The 5.2% stake is just above the 5% threshold, so any further accumulation could signal a more active posture.

DirectionNeutral
Confidencemedium
Horizonweeks
Latest settled — T+20d
HBIO ▲ +5.30% at T+20d
NEUTRAL call +5.30% · α vs SPY +5.86% · entry $7.92 → $8.34
Next anchor: T+60d in 7w
Latest observation: T+23 -7.83% FF3 residual α
Entry = T+0 close
Sep 22, 2026
via day close
T+1d
+1.64%
call +1.64% · α +2.36%
$8.05
settled 5w ago
T+5d
+0.51%
call +0.51% · α +1.69%
$7.96
settled 27d ago
T+20d
+5.30%
call +5.30% · α +5.86%
$8.34
settled 6d ago
T+60d
Pending
in 7w

Price Chart

Loading chart...

Executive Summary

Leviticus Partners LP filed an amended Schedule 13G disclosing a 5.2% passive stake in Harvard Bioscience Inc as of September 14, 2026, holding 235,000 shares. This is a routine passive ownership update with no change in investment intent.

Key Financial Metrics

Stake
5.2%
Investor
Leviticus Partners LP

Key Facts

  • Leviticus Partners LP holds 235,000 shares of Harvard Bioscience Inc common stock
  • Stake represents 5.2% of shares outstanding
  • Filing date: September 22, 2026; event date: September 14, 2026
  • Filer certifies passive intent under Rule 13d-1(b)

Financial Impact

Passive stake of 5.2% — no material financial impact from this filing alone

Risk Factors

  • Potential future activist engagement if stake increases or filing converts to 13D
  • No specific catalyst or change in business outlook disclosed

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0001019432-26-000013
Document: 0001019432-26-000013-index.html0001019432-26-000013
Document: 0001019432-26-000013.txt0001019432-26-000013
12 reports for HBIO
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for HBIO — sortable, filterable
TypeNow
Sep 22, 2026
4w ago
SC 13G/A
NEUTRAL ★ 3/10
$7.92awaiting T+60—$8.32 (+5.05%)
Aug 11, 2026
10w ago
8-K
MIXED ★ 5/10
$6.13awaiting T+60—$8.32 (+35.73%)
Aug 11, 2026
10w ago
8-K
MIXED ★ 6/10
$6.13awaiting T+60—$8.32 (+35.73%)
Jul 28, 2026
12w ago
Press Release
NEUTRAL ★ 1/10
$5.92awaiting T+60—$8.32 (+40.54%)
Jun 2, 2026
20w ago
8-K
NEUTRAL ★ 3/10
$6.50 $7.90▲ +21.54%▲ +19.04%$8.32 (+28.00%)
May 12, 2026
23w ago
8-K
MIXED ★ 5/10
$5.41 $6.19▲ +14.42%▲ +10.03%$8.32 (+53.79%)
May 12, 2026
23w ago
8-K
BEARISH ★ 6/10
$5.41 $6.19▼ −14.42%▼ −10.03%$8.32 (−53.79%)
May 12, 2026
23w ago
Press Release
NEUTRAL ★ 4/10
$5.41 $6.19▲ +14.42%▲ +10.03%$8.32 (+53.79%)
Mar 16, 2026
32w ago
Insider Cluster
NEUTRAL ★ 3/10
$5.01 $6.01▲ +19.96%▲ +9.48%$8.32 (+66.07%)
Mar 16, 2026
32w ago
Insider Cluster
NEUTRAL ★ 3/10
$5.01 $6.01▲ +19.96%▲ +9.48%$8.32 (+66.07%)
Showing 10 of 12

US Market Status

Market Closed — Opens Tue (16h 2m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 22, 2026